NEW YORK, NY --(Marketwired - November 21, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, notifies investors of the class action lawsuit filed against Aeterna Zentaris Inc. ("Aeterna" or the "Company") (
The complaint allegations focus on whether the Company and its executives violated federal securities laws by making false and misleading statements and/or failing to disclose material facts regarding its business and operations.
On November 6, 2014, Aeterna announced that it had received a Complete Response Letter from the Food and Drug Administration indicating that the New Drug Application for the Company's drug Macrilen "cannot be approved in its present form."
Following this news, the price of Aeterna stock declined by $0.64 per share, or nearly 50%, to close on November 6, 2014 at $0.65 per share.
Request more information now by clicking here: www.faruqilaw.com/AETERNA . There is no cost or obligation to you.
Take Action
If you invested in Aeterna stock or options prior to November 6, 2014 and would like to discuss your legal rights, visit www.faruqilaw.com/AETERNA . You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com . Faruqi & Faruqi, LLP also encourages anyone with information regarding Aeterna's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 369 Lexington Avenue, 10th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. Email contact Telephone: (877) 247-4292 or (212) 983-9330
